Sana Biotechnology, Inc.

SANASEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1770121

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Research and Development Expense	$261.8M	$285.9M	$248.6M	$132.9M	$99.6M
Operating Expenses	$293.1M	$272.6M	$356.9M	$286.1M	$141.2M
Operating Income (Loss)	-$293.1M	-$272.6M	-$356.9M	-$286.1M	-$141.2M
Other Nonoperating Income (Expense)	-$52.0K	-$674.0K	$305.0K	$97.0K	-$29.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	—	—	—	—	-$138.3M
Income Tax Expense (Benefit)	$0.00	—	—	—	-$7.5M
Net Income (Loss) Attributable to Parent	-$283.3M	-$269.5M	-$355.9M	-$285.3M	-$130.8M
Earnings Per Share, Basic	-$1.46	-$1.43	-$2.14	-$21.92	—
Earnings Per Share, Diluted	-$1.46	-$1.43	-$2.14	-$21.92	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$501.0M	$565.3M	$822.7M	$1.1B	$730.3M
Assets, Current	$160.8M	$213.5M	$444.4M	$558.1M	$384.5M
Cash and Cash Equivalents, at Carrying Value	$133.5M	$176.8M	$253.0M	$124.8M	$124.8M
Liabilities	$250.5M	$277.8M	$323.4M	$400.9M	$298.6M
Liabilities, Current	$45.4M	$64.5M	$111.5M	$99.2M	$31.5M
Accounts Payable, Current	$5.2M	$4.1M	$2.9M	$2.2M	$2.3M
Stockholders' Equity Attributable to Parent	$499.3M	$728.5M	-$421.2M	-$142.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$253.6M	-$290.1M	-$251.1M	-$138.0M	-$85.5M
Net Cash Provided by (Used in) Investing Activities	$172.0M	$210.6M	-$245.8M	-$252.6M	-$87.9M
Net Cash Provided by (Used in) Financing Activities	$31.6M	$4.9M	$631.8M	$435.7M	$223.7M
Payments to Acquire Property, Plant, and Equipment	$20.0M	$20.9M	$29.9M	$23.9M	$26.1M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)